Palisade Bio (PALI) Net Cash Flow Growth (3y) (2013 - 2026)
Palisade Bio (PALI) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 32.17% |
| 10 | Palisade Bio | 420.38 Mn | 287.75 Mn | - | -41.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.42% |
| Dec 31, 2025 | 334.48% |
| Sep 30, 2025 | -26.43% |
| Jun 30, 2025 | -2.90% |
| Mar 31, 2025 | 12.37% |
| Dec 31, 2024 | 35.60% |
| Sep 30, 2024 | -62.40% |
| Jun 30, 2024 | -81.28% |
| Mar 31, 2024 | -127.64% |
| Dec 31, 2023 | -323.19% |
| Sep 30, 2023 | -12.41% |
| Jun 30, 2023 | 34.72% |
| Mar 31, 2023 | -42.92% |
| Dec 31, 2022 | 9.84% |
| Sep 30, 2022 | 21.47% |
| Jun 30, 2022 | 1.14% |
| Mar 31, 2022 | -29.26% |
| Dec 31, 2021 | -313.00% |
| Sep 30, 2021 | 45.38% |
| Jun 30, 2021 | 86.31% |